Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design

Current Opinion in HIV and AIDS

Volumn 2, Issue 3, 2007, Pages 183-188

  Brander, Christian ^a   Self, Steve ^b   Korber, Bette ^c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b USA   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d SANTA FE INSTITUTE   (United States)

Author keywords

HIV; Immunogen; Protective cellular immunity; Sequence diversity; T cell; Vaccine design

Indexed keywords

ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VACCINATION; VIRUS STRAIN;

EID: 34250647040     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3280f3bfe2     Document Type: Review

References (35)

1. Brander C, Frahm N, Walker BD. The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 2006; 18:430-437.
2. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-2200.
3. Li F, Malhotra U, Gilbert PB, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006; 24:6893-6904. This study by Li et al. provides the first description of the powerful PTE approach, which, by maximizing diversity coverage on a 9-mer basis, achieves significantly improved response rates compared with centralized sequences.
4. Altfeld M, Addo MM, Shankarappa R, et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003; 77:7330-7340.
5. Rutebemberwa A, Currier JR, Jagodzinski L, et al. HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. AIDS 2005; 19:1165-1172.
6. Kesturu GS, Colleton BA, Liu Y, et al. Minimization of genetic distances by the consensus, ancestral, and center-of-tree (COT) sequences for HIV-1 variants within an infected individual and the design of reagents to test immune reactivity. Virology 2006; 348:437-448.
7. + T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005; 79:12952-12960.
8. Haas G, Plikat U, Debre P, et al. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol 1996; 157:4212-4221.
9. Sabado RL, Kilpatrick S, Ali A, et al. Detection of HIV-1-specific CTL responses in clade B infection with clade C peptides and not clade B consensus peptides. J Immunol Methods 2005; 296:1-10.
10. Altfeld M, Allen TM, Kalife ET, et al. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design. J Virol 2005; 79:5000-5005.
11. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76:8757-8768.
12. van Baalen CA, Kwa D, Verschuren EJ, et al. Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity. J Infect Dis 2005; 192:1183-1190.
13. Nickle DC, Jensen MA, Gottlieb GS, et al. Consensus and ancestral state HIV vaccines. Science 2003; 299:1515-1518; author reply 1515-1518.
14. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-2360.
15. Thomson SA, Jaramillo AB, Shoobridge M, et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005; 23:4647-4657.
16. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328:345-348.
17. Plata F, Autran B, Martins LP, et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 1987; 328:348-351.
18. Nixon DF, Townsend AR, Elvin JG, et al. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988; 336:484-487.
19. Leslie A, Kavanagh D, Honeyborne I, et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 2005; 201:891-902.
20. Frahm N, Kiepiela P, Adams S, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7:173-178. This study attributes to subdominant cytotoxic T-lymphocyte responses an important role in HIV control, with obvious implications for vaccine design and in-vitro detection approaches. In addition, the study provides some indication for adaptation of clade C sequences to common immune pressure, which again will need to be considered when translating immunogen from one clade to another.
21. Weaver EA, Lu Z, Camacho ZT, et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 2006; 80:6745-6756.
22. Bhattacharya T, Daniels M, Heckerman D, et al. Founder effects in population based assessment of HIV polymorphisms and HLA allele associations. Science 2007 (in press).
23. Gao F, Weaver EA, Lu Z, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005; 79:1154-1163.
24. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2006 [Epub ahead of print].
25. Kothe DL, Li Y, Decker JM, et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006; 352:438-449. This is one of a number of studies [21,23,24,27] that not only demonstrate the viability of some of the centralized sequences but also demonstrate their in-vivo immunogenicity in mice and rabbits.
26. Liao HX, Sutherland LL, Xia SM, et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006; 353:268-282.
27. Doria-Rose NA, Learn GH, Rodrigo AG, et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 2005; 79:11214-11224.
28. Boggiano C, Moya R, Pinilla C, et al. Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV-1 CTL epitope Gag77-85. Eur J Immunol 2005; 35:1428-1437.
29. Lawendowski CA, Giurleo GM, Huang YY, et al. Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization. J Immunol 2002; 169:2414-2421.
30. Klenerman P, Rowland-Jones S, McAdam S, et al. Naturally occurring HIV-1 gag variants antagonise cytotoxic T cell activity. Nature 1994; 369:403-410.
31. Burgers WA, van Harmelen JH, Shephard E, et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 2006; 87:399-410.
32. Seaman MS, Xu L, Beaudry K, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005; 79:2956-2963.
33. Wilson CC, McKinney D, Anders M, et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 2003; 171:5611-5623.
34. Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100-106. By combining short stretches of the viral genome into 'mosaic' sequences, Fischer et al. show significantly increased sequence diversity, especially for 9-mer peptide sequences representing PTE sequences.
35. + T-cell responses with relative control of infection.